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HAVE EXPANDABLE METALLIC STENTS REPLACED OPERATION
FOR MALIGNANT BILIARY OBSTRUCTION?
ABSTRACT
Gordon, R. L., Ring, E. J., La Berge, J. M. and Doherty, M. M. (1992) Malignant biliary
obstruction: Treatment with expandable metallic stems-Follow-up of 50 consecutive
patients. Radiology, 182:697-701
Lillemoe, K. D., Sauter, P. K., Pitt, H. A., Yeo, C. J. and Cameron, J. L. (1993) Current
status ofsurgical palliation ofperiampullary carcinoma. Surgery Gynecology and Obstet-
rics, 176:1-10
A consecutive series of 50 patients with malignant biliary obstruction were treated by
means of palliative drownage with a metallic expandable stent. Stem placement was
successful in all patients. The patients were followed up prospectively at 2-month intervals
over a period of 9-22 months. Forty-one patients (82%) died; nine (18%) are still living.
The overall patency and survival rates for the 50 patients were 5.8 months and 7.5 months,
respectively. The 30-day mortality rate was 8% (n 4), the minor complication rate was
18% (n 9), and the major complication rate was 8% (n 4). One patient (2%) had
intrahepatic arterial bleeding that required ernbolization, one (2%) had a right subphrenic
abscess, and two patients (4%) had transient septic events. Stem occlusion requiring
a second intervention occurred in 24% of patients (n--12). Excellent palliation was
achieved in most patients. No stent migration occurred. No great clinical advantages in
prolonged patency compared with those of other published series involving the use of
plastic stents were demonstrated. Ease of placement’ and versatility may offset the high
cost of the stent.
In recent years, the use of nonoperative palliation for unresectable periampullary
carcinoma has increased markedly, in part, because of the high morbidity and mortality
rates after surgical palliation. The current analysis was undertaken to determine whether
or not decreases in morbidity and mortality rates, recently observed after resection of
periarnpullary carcinoma, are now being seen in the surgical palliation of unresectable
periarnpullary carcinoma. During a 54 month period, 118 consecutive patients underwent
surgical exploration with the finding of unresectable periampullary adenocarcinoma.
Jaundice was the most common complaint at admission, being present in 73
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per cent ofthe patients. Abdominal or back pain, or both, was present in 71 per cent ofthe
patients and weight loss was observed in 61 per cent of the patients. The most commonly
performed procedure was combined biliary bypass and gastrojejunostomy, being per-
formed upon 75 per cent ofthe patients.A gastroje-junostomy was performed upon 107 of
118 patients (91 per cent). The hospital mortality rate was 2.5 per cent. Postoperative
complications occurred in 37 per cent of the patients but were seldom life-threatening.
Wound infection was the most frequent postoperative complication (10 per cent),
followed by cholangitis (8 per cent) and delayed gastric emptying (8 per cent). During the
late follow-up period, only 4 per cent of the patients had gastric outlet obstruction, and
only 2 per cent had recurrent jaundice. The mean survival time postoperatively was 7.7
months. These results demonstrate that patients with unresectable periampullary car-
cinoma can undergo surgical palliation with minimal perioperative mortality, acceptable
morbidity and good long term palliation. We conclude that surgical palliation is the
treatment of choice for carefully selected patients with unresectable periampuilary
carcinoma. Surg. Gynecol. Obstet., 1993, 176" 1-10.
KEYWORDS: Malignant biliary obstruction carcinoma of the pancreas ob-
structive jaundice expandable metallic stents hepatico-
jejunostomy.
PAPER DISCUSSION
During the 1980s percutaneous transhepatic stenting
and endoscopic transpapillary stenting have become
established methods for the palliation of jaundice in
patients with malignant obstruction of the ex-
trahepatic biliary tree. Several types of biliary endo-
prosthesis are now available, with large lumens
ranging from 9 to 14 Fr in external diameter. Stent
materials include Teflon* (E. I. du Pont, Wilmington,
Delaware, USA), polyethylene and Percuflex*
(MediTech, Watertown, Massachusetts, USA). Our
review of articles published during 1983-1991 showed
high success rates in terms of jaundice relief: between
76-100 per cent following percutaneous stent and
82-100 per cent following endoscopic stent. However,
these types of endoprosthesis carry a high late compli-
cation rate, 28 per cent on average 1. The major late
complication leading to recurrent jaundice or cholan-
gitis is clogging of the endoprosthesis, which occurs in
20-30 per cent of cases (whether placed from above or
below). The self-expandable metal stent, Wallstent*
(Medinvent SA, Lausanne, Switzerland)seems to solve
the problem of clogging.
Davids and colleagues conducted a randomised trial
of self-expandable stents (Wallstent*) versus polyethy-
lene-stents; both were placed endoscopically for distal
malignant biliary obstruction2. The polyethylene stent
used in this trial was a straight (10 Fr) endoprosthesis
with two side flaps to prevent dislocation and a side
hole at each end (PBN Medicals, Stenloese, Denmark).
One hundred and five patients were included in this
trial: 49 received a metal stent and 56 a straight poly-
ethylene stent. The median period of patency was
longer in the metal-stent group than in the polyethy-
lene-stent group (273 days versus 126 days: P 0.006).
Stent occlusion occurred in 16 patients (33 per cent) in
the metal-stent group after a median of 273 days
compared with 30 patients (54 per cent) in the poly-
ethylene-stent group after a median of 126 days. The
main cause of metal-stent occlusion was tumour in-
growth through the meshes, whereas the main cause of
polyethylene-stent occlusion was sludge encrustation.
Another report from the European Wallstent Study
Group included 103 patients with malignant biliary
obstruction from eight European endoscopy centres
who underwent biliary decompression by means of
Wallstent endoprosthesis. Although insertion of the
stent was successful in nearly 100 per cent, long-term
complications manifested by late cholangitis were seen
in 18 patients after a median interval of 125 days. The
cause of cholangitis was haemobilia in one case, distal
tumour overgrowth in four, tumour ingrowth through
the meshes of the stent in seven, biliary sludge obstruc-
tion in two, proximal bile duct compression in one and
unknown in three.
It appears from these two studies that the occlusion
rate by biliary sludge after metal stents is substantially
less than that reported after polyethylene stents (21 per
cent after a median time interval of 154 days4). How-
ever, the incidence of stent obstruction after metal
stents is still high, being mostly caused by tumourHPB INTERNATIONAL 153
ingrowth through the meshes of the stent or tumour
overgrowth at either end. The paper by Dr. Gordon
and colleagues shared these experiences. Fifty patients
with malignant biliary obstruction were treated by
a Wallstent: 24 patients had pancreatic carcinoma, 15
cholangiocarcinoma, 6 metastatic carcinoma from
a variety ofprimary sites and 5 gallbladder carcinoma.
Of these, nine patients (18 per cent) developed minor
complications, four (8 per cent) major complications
and four (8 per cent) died within 30 days of the pro-
cedure. Although stent placement was successful in all
and early excellent palliation was achieved in most
patients, twelve of fifty patients (24 per cent) had stent
occlusion requiring one or more further interventions
such as placement of additional stents (n 11) or dis-
impaction of the sludge (n 1). The causes of stent
occlusion were tumour overgrowth in 10 cases, stent
clogging by sludge and debris in one and uncertain in
one. During the follow-up period of9-22 months, there
was no great improvement in patency for the Wallstent
endoprosthesis compared with that for plastic stents
reported by other studies. Due to the increasing use of
this expandable stent during the past few years, more
and more new complications have been reported (e.g.
haemorrhage due to erosion of the stent through the
duodenal wall s and acute pancreatitis6).
Surgical biliary-enteric bypass has been accepted for
years as the procedure of choice to cope with obstruc-
tive jaundice due to irresectable malignant tumours.
The report from Dr. Lillemoe and colleagues from the
Johns Hopkins Medical Institutions confirms this
statement. Among 118 patients with irresectable
periampullary tumours who underwent palliative bili-
ary bypass (89 cases or 75 per cent had combined
biliary bypass and gastrojejunostomy), the hospital
mortality rate was only 2.5 per cent and the 30-day
mortality rate was 3.3 per cent. Recurrent jaundice
occurred in only 2 per cent of those who survived the
operation (two patients, at 6 and 12 months post-
operatively). This experience was comparable to our
own. Twenty-five patients with irresectable pancreatic
head carcinoma underwent single-loop biliary and
gastric bypass without a hospital death; two patients
(8 per cent) had recurrent jaundice due to multiple
liver metastases7, but none developed renewed gastric
outlet obstruction. By contrast, five patients in
Lillemoe’s series had gastric outlet obstruction at
3, 5, 5, 7 and 10 months postoperatively; in four ofthese
five a gastrojejunostomy had been performed. These
low figures for 30-day mortality and late complications
(notably recurrent jaundice) in Lillemoe’s series and
our own compare well with those obtained by met-
analysis of 23 articles published between 1980-1990
(12 per cent deaths, 16 per cent late complications) 1.
During the past decade, there have been several
studies reporting the outcome of nonoperative and
operative treatment of irresectable periampullary tu-
mours 1. It can be concluded that operative and
nonoperative techniques are equally effective in the
short-term relief of jaundice, but operation offers a
better long-term result. Many prospective randomised
trials, particularly those published before 1990, showed
that the surgical arm was associated with a higher
mortality rate (20-24 per cent versus 8-20 per
cent)a- 0; these articles are usually quoted by authors
who prefer nonoperative measures. There seems to
have been a sharp drop in the mortality rate of palli-
ative surgical bypass during the past few years7’1’2
(and Lillemoe’s paper), and this improvement rein-
forces our belief that an operative approach should be
preferred in reasonably fit patients. Not only can
laparotomy assess the resectability ofthe tumour more
accurately than any imaging studies, but it can also
palliate most symptoms at the same time (including
pain) by the performance of biliary bypass, gastroen-
terostomy and chemical splanchnicectomy. Moreover,
operation should forestall late complications, such as
recurrentjaundice or.duodenal obstruction. This bene-
fit is important for any palliative procedure, since
improvement in the quality oflife is the principal aim of
treatment.
We believe that the absence of late obstructive com-
plications requiting readmission to hospital and the
certainty that a resectable tumour is not overlooked
are the mainjustifications for an operative approach to
periampullary tumour. Expandable metallic stents
have a role in patients with high surgical risk or those
with very advanced tumour, Whose life expectancy is
less than a couple of months.
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DOES PROPHYLACTIC ENDOSCOPIC SCLEROTHERAPY
PREVENT VARICEAL BLEEDING OR NOT? A QUESTION OF
EXPERIMENTAL DESIGN
Some circumstantial evidence is very strong,
as when you find a trout in the milk Thoreau
ABSTRACT
l/an Thiel, D. H., Dindzans, V. J., Schade, R. R., Rabinovitz, M. and Gavaler, J. S. (1993)
Prophylactic versus emer#ency sclerotherapy of lar#e esopha#eal varices prior to liver
transplantation. Di#estive Diseases and Sciences; 38 1505-1510
From January 1985 through July 1987, adult patients accepted for liver transplantation
with large esophageal varices were enrolled in a study evaluating the use ofprophylactic vs
emergency sclerotherapy. Six hundred forty-eight subjects received prophylactic sclero-
therapy, and 172 received emergent sclerotherapy. Esophageal stricture formation was
increased 12.9-fold (P < 0.001), esophageal perforation 6.4-fold (P < 0.005), and post-
sclerotherapy bleeding esophageal ulcers 3.7-fold (P< 0.001) in those receiving emerg-
ency sclerotherapy as opposed to prophylactic sclerotherapy. These differences were even
greater if the number of sclerotherapy sessions rather than the number of patients was
used as the denominator for the comparisons. In total, 19.6% ofemergency sclerotherapy
cases were associated with an untoward outcome of sclerotherapy; only 1.9% of cases
receiving prophylactic sclerotherapy experienced an untoward outcome (P < 0.001).
These data demonstrate that leinergency sclerotherapy is associated with a greater
prevalence of complications and support earlier studies that show that sclerotherapy